Sarah, Author at Biologics by McKesson

BESREMi (ropeginterferon alfa-2b-njft), FDA Approved for Treatment of Polycythemia Vera, Available at Biologics by McKesson

Dec 6, 2021 | Press Release

CARY, N.C., Dec. 6, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by PharmaEssentia USA Corporation as a specialty pharmacy provider for BESREMi® (ropeginterferon alfa-2b-njft) for the...

Newly Approved LIVTENCITY (maribavir) Now Available at Biologics by McKesson

Dec 3, 2021 | Press Release

CARY, N.C., Dec. 3, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Takeda Pharmaceuticals as a specialty pharmacy provider for LIVTENCITY™ (maribavir) indicated for the treatment of adults...

Aplastic Anemia/MDS International Foundation Q&A

Nov 19, 2021 | Patient Advocacy

What is the Aplastic Anemia and MDS International Foundation? The Aplastic Anemia and MDS International Foundation (AAMDSIF) is dedicated to assisting and supporting people who have bone marrow disorders, including aplastic anemia, myelodysplastic syndrome and...

EXKIVITY (mobocertinib), First and Only FDA Approved Oral Treatment of EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer, Available at Biologics by McKesson

Nov 3, 2021 | Press Release

CARY, N.C., NOVEMBER 3, 2021—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Takeda Pharmaceutical Limited Company as a specialty pharmacy provider for EXKIVITY™ (mobocertinib) for the...

National Neutropenia Network Q&A

Oct 12, 2021 | Patient Advocacy

What is the National Neutropenia Network? The National Neutropenia Network (NNN) is a non-profit organization based in Michigan that was started in 1994 to support neutropenia patients and their loved ones. Neutropenia is a very rare blood condition in which there are...